Wegovy vs Ozempic: Same Drug, Different Dose — Side Effects, Cost & What Your Body Needs on Both (2026)

Wegovy and Ozempic: Same Drug, Different Label

Wegovy and Ozempic are both brand names for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. The drug works identically in both products, it mimics the GLP-1 hormone, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. The only differences are the FDA-approved indication, maximum dose, and how insurance covers them.

Understanding this is the single most important thing about the Wegovy-vs-Ozempic comparison: you are not choosing between two different medications. You are choosing between two labels for the same molecule at different doses, with different insurance pathways. Every side effect, every mechanism, every interaction is shared because the drug is identical.

The dose difference matters more than most articles acknowledge. Ozempic's standard maintenance doses (0.5 mg to 2.0 mg per week) are significantly lower than Wegovy's target of 2.4 mg per week. Since semaglutide's effects on appetite, weight loss, and side effects are all dose-dependent, this single variable drives nearly every meaningful difference between the two products. A person on Ozempic 2.0 mg and a person on Wegovy 2.4 mg are having more similar experiences than either of them would with someone on Ozempic 0.5 mg, even though all three are technically "on semaglutide."

An oral form of semaglutide also exists. Rybelsus was the original oral semaglutide (approved for type 2 diabetes), and as of January 2026, an oral form of Wegovy received FDA approval. Oral absorption of semaglutide is lower and more variable than injectable, which is why the oral doses are much higher in milligrams. If you prefer not to inject, discuss oral options with your prescriber, but be aware that GI side effects may differ in timing and intensity with oral administration because the drug passes through the stomach rather than entering the bloodstream directly.

The practical implication: if your doctor prescribes Ozempic for diabetes and you lose weight as a side effect, you are experiencing the same pharmacological process as someone on Wegovy, just at a lower dose. Conversely, if insurance covers Wegovy for weight management but not Ozempic off-label for the same purpose, that is a coverage distinction, not a medical one.

Side Effects Compared: Why Wegovy Users Report More Problems

The side effect profiles of Wegovy and Ozempic are identical in type but differ in frequency, because frequency is dose-dependent. At Wegovy's higher maintenance dose (2.4 mg), 44% of trial participants reported nausea compared to roughly 20% on Ozempic's typical doses. The pattern holds for vomiting, diarrhea, and constipation, same symptoms, higher incidence at higher doses.

The STEP 1 trial (Wilding et al., 2021; PMID 33567185) enrolled 1,961 adults and found GI adverse events in 74.2% of the semaglutide 2.4 mg group versus 47.9% on placebo. That 74.2% figure sounds alarming, but context matters: only 4.5% of participants actually discontinued due to GI events. For most people, the nausea peaked during dose escalation (weeks 4-8) and improved significantly once they reached maintenance dose.

A pooled analysis of STEP 1-3 by Wharton et al. (2022; PMID 34514682) made an important finding: of the 7.6%-14.4% additional weight loss with semaglutide versus placebo, less than 1 percentage point was mediated by GI side effects. The vast majority of weight loss came from reduced appetite, not from being too nauseous to eat. This means that managing side effects does not meaningfully reduce the drug's effectiveness: a critical point for anyone hesitating to address their symptoms.

There is one nuance worth noting: research suggests that fewer people experience side effects on Ozempic compared to Wegovy, likely because Ozempic maxes out at a lower dose. If you are someone who experiences severe GI symptoms at higher semaglutide doses, discussing a lower maintenance dose with your prescriber (effectively an Ozempic-range dose) is a legitimate medical option, not a treatment failure. For a complete overview of GI management strategies, see our GLP-1 side effects guide.

Beyond GI: Hair Loss, Muscle Loss, and "Ozempic Face"

The non-GI side effects of semaglutide (hair thinning, muscle loss, and facial volume changes) are not direct drug effects. They are consequences of rapid, significant weight loss and reduced caloric intake. Any intervention that produces 15% body weight loss in 68 weeks would cause the same issues. This means they apply equally to Wegovy and Ozempic users who lose substantial weight.

Hair thinning (telogen effluvium): Rapid weight loss disrupts the hair growth cycle, pushing more follicles into the resting (telogen) phase. Hair shedding typically appears 3-6 months after significant weight loss begins and is usually temporary, regrowth occurs after weight stabilizes. A 2026 review by Leite Júnior and Ribeiro Junior ( PMID 42873315) found hair loss prevalence ranged from 3-7% in controlled trials to over 70% in real-world cohorts, with telogen effluvium the predominant pattern. Nutritional factors, particularly iron, ferritin, zinc, biotin, and protein status, influence severity. For a detailed evidence review, see our GLP-1 and hair loss guide.

Muscle loss: Body composition data from the STEP 1 trial showed that both fat mass and lean mass decreased during weight loss. This is physiologically expected during any caloric deficit, your body does not selectively lose only fat. The clinical concern is that losing too much muscle accelerates age-related decline in strength, metabolic rate, and bone density. Resistance training and adequate protein intake (1.2-1.6 g/kg/day) are the primary evidence-based countermeasures. See our muscle preservation guide for GLP-1 users for the full protocol.

"Ozempic face": Facial volume loss after significant weight loss (hollow cheeks, more prominent bone structure) is not unique to semaglutide. It occurs with any substantial weight reduction and is a cosmetic concern, not a medical one. It is entirely reversible with weight regain, and cosmetic fillers can address it if desired.

Fatigue: Fatigue is a commonly reported semaglutide side effect (real-world reports cite roughly 29%, though it is not consistently captured as a discrete endpoint in the pivotal trials), which can stem from reduced caloric intake, electrolyte shifts, dehydration, or the metabolic adjustment to significant weight loss. Managing fatigue requires addressing its root cause (usually inadequate nutrition on reduced appetite) rather than treating it as a standalone symptom. Our Ozempic fatigue guide covers the seven most common causes and their fixes.

The Nutritional Gap: What Both Drugs Create

Whether you take Wegovy or Ozempic, reduced appetite means reduced food intake, which means reduced nutrient absorption. A KFF poll (November 2025) found that many GLP-1 users struggle to maintain adequate nutrition. The nutrients most at risk are protein, iron, B vitamins, calcium, vitamin D, magnesium, and fiber, all of which require active management when food intake drops significantly.

This is the part of the Wegovy-vs-Ozempic conversation that matters most for your health outcomes. The drug comparison is academic, same molecule, different dose. But the nutritional management applies to everyone on semaglutide regardless of brand, and it is where most users need the most help.

When appetite drops by 30-40% (common on maintenance doses), even people who ate well before starting treatment face nutritional deficits. The math is simple: if you previously ate 2,000 calories and now eat 1,200-1,400, you are getting 30-40% less of every nutrient unless you deliberately prioritize nutrient-dense foods and targeted supplementation.

The nutrients that require the most attention on semaglutide:

Nutrient	Why It's at Risk	Signs of Deficiency	How to Address
Protein	Reduced appetite → eating less at every meal	Muscle loss, hair thinning, weakness	1.2-1.6 g/kg/day, prioritize at every meal
Iron	Lower meat intake, GI side effects impair absorption	Fatigue, hair loss, pale skin, cold hands	Monitor ferritin levels; supplement if low
Vitamin D	Less food, less fatty fish, less dairy	Bone weakness, fatigue, mood changes	2,000-4,000 IU/day; test levels
Vitamin B12	Reduced meat intake, slower gastric emptying	Fatigue, numbness, cognitive fog	Methylcobalamin supplement or sublingual
Magnesium	Reduced food volume, GI losses from diarrhea	Cramps, insomnia, anxiety, constipation	300-400 mg glycinate at bedtime
Calcium	Reduced dairy intake, lower overall food volume	Long-term: bone density loss	Dietary sources first; supplement with D3+K2
Fiber	Eating less food overall → less fiber	Constipation (compounded by GLP-1 effect)	Psyllium husk; increase slowly to avoid GI flare
Omega-3 DHA	Reduced fish and fat intake	Inflammation, dry skin, mood changes	1,000 mg DHA+EPA from algae or fish oil

The clinical reality is that most people do not realize they are becoming nutrient-depleted until symptoms appear, and by that point, the deficit has been building for weeks or months. Fatigue attributed to "the drug" may actually be iron deficiency. Hair loss blamed on "semaglutide" may be driven by protein and zinc insufficiency. Mood changes assumed to be "hormonal" may reflect vitamin D or magnesium depletion. This is why proactive testing and supplementation (starting when you begin the drug, not after symptoms develop) produces meaningfully better outcomes.

A practical starting protocol for anyone beginning semaglutide (Wegovy or Ozempic) includes: a baseline blood panel (CBC, complete metabolic panel, iron/ferritin, vitamin D, B12, magnesium, thyroid function), protein tracking (aim for 1.2-1.6 g/kg/day, which for a 180 lb person means 98-131 grams daily), a quality multivitamin covering baseline micronutrients, and targeted supplementation for the highest-risk nutrients (vitamin D3, magnesium glycinate, and B12). For the full evidence-based protocol, see our supplements for GLP-1 users guide.

For a complete supplementation protocol organized by priority, see our supplements for GLP-1 and Ozempic users guide and the GLP-1 nutrition checklist. For Mounjaro and Zepbound users specifically, see our vitamins to take on Mounjaro guide.

Wegovy vs Ozempic for Weight Loss: The Numbers

In clinical trials, Wegovy (semaglutide 2.4 mg) produced roughly 15% body weight loss over 68 weeks, while Ozempic at its FDA-approved diabetes doses (0.5-2.0 mg) typically produces 5-7% weight loss. The difference is almost entirely dose-dependent. A head-to-head comparison is complicated by the fact that Ozempic's trials enrolled people with type 2 diabetes, while Wegovy's enrolled people with obesity, different starting populations with different metabolic profiles.

The STEP 1 trial showed that 86.4% of participants on semaglutide 2.4 mg achieved at least 5% weight loss, and 69.1% achieved at least 10%. For context, achieving just 5% body weight loss produces clinically meaningful improvements in blood pressure, blood sugar, and cholesterol according to the American Heart Association.

It is also worth noting that weight regain after stopping semaglutide is well-documented. The STEP 4 withdrawal trial showed that participants who switched from semaglutide to placebo regained weight over the following year. GLP-1 drugs are chronic treatments, not short courses: a consideration that makes nutritional management during treatment even more important, because most users will be on the drug for years. For people considering stopping, see our coming off Ozempic guide.

Cost and Insurance: The Real Deciding Factor

For most people, the Wegovy-vs-Ozempic decision is made by insurance coverage, not by pharmacology. Without insurance, Wegovy lists at approximately $1,349/month and Ozempic at approximately $935-$1,112/month. With insurance, out-of-pocket costs vary dramatically, from $0 to several hundred dollars per month depending on plan, diagnosis, and prior authorization requirements.

The insurance landscape matters because the FDA-approved indication determines coverage. If you have type 2 diabetes, insurance will typically cover Ozempic. If you have obesity without diabetes, Wegovy is the approved option, but many insurers still exclude weight management drugs or require extensive prior authorization. As of 2026, Medicare covers GLP-1 medications for both diabetes and, under expanded provisions, for obesity in some circumstances.

Compounded semaglutide: which was widely available from compounding pharmacies during the FDA shortage period, added another cost dimension. Compounded versions typically cost $200-$500/month, significantly less than brand-name products. However, the FDA has been moving to restrict compounded semaglutide as the shortage resolves, and the long-term availability and quality assurance of compounded versions remain uncertain. If you are using compounded semaglutide, discuss the transition plan with your prescriber, because switching to brand-name Wegovy or Ozempic may change your dose, injection device, and cost simultaneously.

Another cost consideration that most comparisons overlook: the cost of managing nutritional deficiencies caused by GLP-1 treatment. Blood panels ($100-$300 without insurance), a registered dietitian consultation ($100-$250/session), and ongoing supplementation ($30-$80/month) are real expenses that should be factored into the total cost of semaglutide treatment. These costs apply equally to Wegovy and Ozempic users.

This creates a practical situation where many people use Ozempic off-label for weight loss because their insurance covers it for diabetes but would not cover Wegovy for weight management. This is between you and your prescriber, but pharmacologically, the drug you are receiving is the same. For a full breakdown of costs across plans, see our GLP-1 cost and insurance guide.

Wegovy HD: The New Higher-Dose Option (2026)

In March 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg), a higher-dose formulation designed to boost weight loss for people who plateau on the standard 2.4 mg dose. Early indirect treatment comparisons suggest it produces greater weight loss than standard Wegovy, but the GI side effect profile is expected to be more pronounced given the higher dose. This is the same dose-dependent pattern seen throughout semaglutide research: more drug, more effect, more side effects.

Wegovy HD represents an important shift in the GLP-1 landscape, it signals that pharmaceutical companies see room for even higher-dose options, and it widens the dose range available to prescribers. For patients who have tolerated 2.4 mg well but want more weight loss, Wegovy HD provides that option without switching to a different molecule.

The nutritional implications of Wegovy HD are straightforward: at higher doses, appetite suppression is even more pronounced, meaning food intake drops further. Every nutritional risk discussed in this article (protein deficit, vitamin depletion, mineral gaps) is amplified at 7.2 mg. If you are considering Wegovy HD, proactive supplementation is not optional; it is essential. Discuss a complete nutritional support plan with your healthcare provider before dose escalation, and consider working with a registered dietitian who specializes in GLP-1 nutrition management.

What About Zepbound and Mounjaro?

Zepbound (tirzepatide, by Eli Lilly) is the main competitor to Wegovy and works through a dual mechanism, activating both GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater weight loss than semaglutide: a substantially higher proportion of Zepbound users achieved at least 15% weight loss compared to Wegovy. If your insurance covers Zepbound, it may be the more effective option, though GI side effects are similar.

Mounjaro is to Zepbound what Ozempic is to Wegovy: same drug (tirzepatide), different FDA-approved indication (Mounjaro for type 2 diabetes, Zepbound for weight management). The nutritional management challenges are identical across all four brands because all GLP-1-class drugs reduce appetite and food intake. See our Mounjaro vitamin guide for tirzepatide-specific nutritional recommendations.

Dose Escalation: The Schedule That Determines Your Side Effects

Both Wegovy and Ozempic use a gradual dose escalation schedule over 16-20 weeks. This is not optional, it is specifically designed to let your GI system adapt to semaglutide. Skipping steps or escalating faster than scheduled is the most common cause of severe nausea and vomiting that leads to discontinuation.

The Wegovy escalation schedule works as follows: 0.25 mg for weeks 1-4, then 0.5 mg for weeks 5-8, then 1.0 mg for weeks 9-12, then 1.7 mg for weeks 13-16, and finally the maintenance dose of 2.4 mg from week 17 onward. Ozempic follows a similar but shorter escalation to a lower maintenance dose: 0.25 mg for weeks 1-4, then 0.5 mg for weeks 5-8, with optional increases to 1.0 mg and then 2.0 mg at 4-week intervals based on glycemic response.

The important clinical guidance: if side effects at your current dose have not resolved, do not increase. Talk to your prescriber about staying at the current dose longer or settling at a lower maintenance dose. Clinical data shows that even lower doses of semaglutide produce meaningful weight loss: the difference between 1.0 mg and 2.4 mg is a matter of degree, not a binary of working versus not working. A dose you can tolerate and take consistently for years will produce better long-term results than a higher dose you abandon after three months.

During the escalation phase (particularly weeks 4-8, when nausea peaks), nutritional management is most critical. Your appetite may drop sharply, nausea may make eating difficult, and the temptation to eat very little is strong. This is precisely when nutrient gaps begin to form. Even if you eat less volume, prioritize protein and nutrient density at every meal. A 400-calorie meal of grilled chicken, spinach, and sweet potato does fundamentally different nutritional work than a 400-calorie meal of crackers and broth, even though both may feel equally manageable on a nauseous stomach.

Managing Semaglutide Side Effects: Practical Steps

The most effective side effect management strategy is the same for both Wegovy and Ozempic: slow dose escalation, eating protein first at every meal, staying hydrated, and proactively supplementing nutrients that decline with reduced food intake. Do not skip dose escalation steps to reach a higher dose faster, this is the single most common cause of severe GI symptoms.

For nausea: Eat small, protein-rich meals rather than large portions. Avoid fried, greasy, or very rich foods during dose escalation. Time your injection when side effects will be least disruptive (many users inject on Friday evening so the worst passes over the weekend). Ginger tea or ginger supplements may help mild nausea.

For constipation: This is often the most persistent GI symptom. Adequate hydration (at minimum 2 liters/day), gradual increase in fiber intake, and magnesium glycinate at 300-400 mg before bed can help, magnesium both supports bowel regularity and addresses the magnesium gap that reduced eating creates.

For fatigue: Rule out dehydration and inadequate caloric intake first. If you are eating less than 1,000 calories/day, you are not eating enough even on a GLP-1, talk to your provider. B12, iron, and vitamin D deficiencies all cause fatigue and should be tested. See our Ozempic fatigue guide.

For hair thinning: Ensure protein intake is at least 1.2 g/kg/day, test and correct iron/ferritin (ferritin should be above 40-70 ng/mL for optimal hair growth), and consider biotin if intake is low. Hair shedding from weight loss is temporary but distressing, understanding the timeline (onset at 3-6 months, resolution after weight stabilizes) helps manage expectations. Full evidence review in our hair loss guide.

Exercise on Semaglutide: Why Resistance Training Is Non-Negotiable

Body composition analysis from the STEP trials showed that roughly 30-40% of weight lost on semaglutide came from lean mass (muscle, organ tissue, bone), not just fat. This ratio is typical for caloric-deficit-driven weight loss at any speed, but at 15% total body weight loss, the absolute amount of lean mass lost becomes clinically significant, particularly for people over 40, who are already losing muscle at 1-2% per year from sarcopenia.

Resistance training is the single most important behavioral intervention for semaglutide users, more impactful than cardio for long-term health outcomes. Muscle tissue drives resting metabolic rate, protects joints, supports bone density, and determines functional independence in later decades. Losing it during pharmacological weight loss accelerates the very aging processes that obesity itself worsened.

The minimum effective dose for muscle preservation during caloric deficit, based on resistance training literature, is 2-3 sessions per week targeting major muscle groups with progressive overload. Combined with adequate protein (1.2-1.6 g/kg/day), this can shift the lean-mass-to-fat-mass ratio of weight loss substantially in favor of fat loss. Some users also add creatine monohydrate (3-5 g/day), which has extensive published evidence for supporting lean mass retention during caloric deficit and improving strength output in resistance training. See our GLP-1 muscle loss prevention guide for the full protocol.

The irony of GLP-1 treatment is that reduced appetite (the mechanism that drives weight loss) also makes it harder to eat enough protein to protect muscle. This is why meal planning and supplementation on semaglutide require more deliberate effort than eating intuitively. When you are not hungry, eating 130 grams of protein per day requires planning, protein shakes, Greek yogurt, collagen in coffee, chicken at every meal. It is not impossible, but it does not happen by accident.

Which Should You Choose: Wegovy or Ozempic?

The decision between Wegovy and Ozempic is rarely yours to make independently, it depends on your diagnosis, insurance coverage, and prescriber recommendation. If you have type 2 diabetes, Ozempic is the FDA-approved choice with better insurance coverage. If your primary goal is weight management without diabetes, Wegovy is the FDA-approved option. In both cases, the drug is the same; the differences are regulatory, financial, and dose-related.

Choose Wegovy if: Your primary goal is weight loss, you do not have type 2 diabetes, your insurance covers it (or you can afford list price), and you are comfortable with the higher maximum dose and corresponding higher side effect frequency.

Choose Ozempic if: You have type 2 diabetes (insurance will cover it), you want a lower maximum dose with generally milder GI side effects, or your insurance covers Ozempic but not Wegovy.

Regardless of which you choose: The nutritional management is identical. Reduced food intake creates the same nutrient gaps whether the label says Wegovy or Ozempic. Prioritize protein at every meal, supplement the nutrients listed above, maintain resistance training to preserve muscle, and work with your healthcare provider on dose titration if side effects are severe.

For the complete nutritional support protocol, see our supplements for GLP-1 users guide.

The Long-Term Perspective: What Happens After Year One

Most clinical trial data on semaglutide extends to 68-104 weeks. The STEP 5 trial showed that weight loss was maintained through two years of continued treatment, but the STEP 4 withdrawal study demonstrated significant weight regain within one year of stopping. This means most users should plan for long-term treatment, and long-term nutritional management alongside it.

The two-year data from STEP 5 showed that participants maintained approximately 15% weight loss through week 104 with continued semaglutide. Side effects generally improved substantially after the first 12-16 weeks, with most patients reporting minimal GI symptoms at steady-state doses. This is encouraging: the worst period is the first few months, and long-term tolerability is genuinely good for most people.

However, the chronic nature of treatment raises questions that short-term trials do not answer. What happens to bone density after years of reduced calcium intake? How does prolonged reduced food intake affect the gut microbiome? Do nutrient deficiencies compound over time if supplementation is not proactive? These are active areas of research, and the honest answer is that long-term data beyond two years is still limited for weight-management doses.

What we do know: the nutritional management that matters in month one matters even more in year two. A minor magnesium deficit at month three becomes a significant deficit at month eighteen if not addressed. Hair thinning that resolves after weight stabilization in the first year can recur if nutritional status deteriorates. Building sustainable eating and supplementation habits early (rather than treating them as temporary additions) is the most important thing you can do for long-term success on either Wegovy or Ozempic.

For users thinking about eventually discontinuing, our coming off Ozempic guide provides a nutrition and exercise protocol designed to minimize rebound weight gain by building the metabolic and behavioral foundations before tapering off the drug.

Frequently Asked Questions

Are Wegovy and Ozempic the same drug?

Yes. Both contain semaglutide, manufactured by Novo Nordisk. The difference is the FDA-approved indication (Wegovy for weight management, Ozempic for type 2 diabetes), the maximum dose (Wegovy goes higher), and insurance coverage pathways. The molecule, mechanism, and side effect profile are identical.

Why does Wegovy cause more side effects than Ozempic?

Because Wegovy is typically prescribed at a higher dose. Semaglutide side effects are dose-dependent, higher doses produce more frequent GI symptoms. At equivalent doses, the side effect rates would be the same because it is the same drug.

Can I switch from Ozempic to Wegovy?

Yes, with your prescriber's guidance. Many patients transition from Ozempic to Wegovy when their treatment goal shifts from diabetes management to weight loss, or when insurance coverage changes. The dose transition should be managed by your healthcare provider to avoid a sudden dose jump that triggers GI side effects.

Do I need to take vitamins on Wegovy or Ozempic?

Most users benefit from targeted supplementation because reduced appetite leads to reduced nutrient intake. The highest-priority nutrients to monitor are protein, iron, vitamin D, B12, and magnesium. A complete protocol is covered in our GLP-1 supplement guide.

Does hair loss happen on both Wegovy and Ozempic?

Hair thinning (telogen effluvium) can occur with either drug because it is caused by rapid weight loss, not by semaglutide directly. It is more commonly reported with Wegovy because Wegovy users typically lose more weight faster. The condition is usually temporary and resolves after weight stabilizes. Nutritional support (especially protein, iron, and zinc) can reduce severity.

Is one better for long-term use?

Both are intended for long-term use. Clinical trial data extends to two years (STEP 5), showing maintained weight loss with continued semaglutide and weight regain after discontinuation. The choice between Wegovy and Ozempic for long-term use depends on your evolving diagnosis, insurance coverage, and tolerance of side effects at different doses.

Can I drink alcohol on Wegovy or Ozempic?

Semaglutide does not have a direct pharmacological interaction with alcohol, but many users report reduced alcohol tolerance. Alcohol also worsens GI side effects (particularly nausea) and can cause hypoglycemia in people taking semaglutide for diabetes. Moderation is advised, and many users find they naturally drink less due to reduced desire. See our GLP-1 and alcohol guide for detailed evidence.

What about natural GLP-1 alternatives?

Several foods and compounds stimulate GLP-1 release naturally, including fiber, protein, yerba mate, and specific probiotic strains (Akkermansia muciniphila). These do not produce anywhere near the pharmacological effect of injectable semaglutide, but they can support GLP-1 function for people who are not candidates for medication or who want to optimize their response while on treatment. Our natural GLP-1 guide covers the evidence for each.

How much weight will I lose on Wegovy vs Ozempic?

In clinical trials, Wegovy at 2.4 mg produced average weight loss of about 15% of body weight over 68 weeks (for a 220 lb person, roughly 33 lbs). Ozempic at diabetes doses typically produces 5-7% weight loss. Individual results vary widely based on starting weight, diet, exercise, genetics, and dose titration. Our GLP-1 weight loss guide provides detailed expectations by drug and dose.